TSC-201-B0702 / TSCan Therap - LARVOL DELTA

TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=840 | Active, not recruiting | Sponsor: TScan Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Pan tumor • Anal Carcinoma • Cervical Adenocarcinoma • Cervical Cancer • Colorectal Cancer • Cutaneous Melanoma • Head and Neck Cancer • Infectious Disease • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Oropharyngeal Cancer • Ovarian Cancer • Penile Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Vaginal Cancer • Vulvar Cancer • HLA-A • HLA-C • PRAME

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (TScan Therap Press Release) - "Updates from the PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials anticipated by end of year; On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year...Plans to present additional data from the ALLOHA Phase 1 trial by the end of the year, including two-year relapse data on the initial patients."

Commercial • IND • P1 data • Trial status • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • Solid Tumor

TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=840 | Recruiting | Sponsor: TScan Therapeutics, Inc. | N=100 ➔ 840

Enrollment change • Anal Carcinoma • Cervical Adenocarcinoma • Cervical Cancer • Colorectal Cancer • Cutaneous Melanoma • Head and Neck Cancer • Infectious Disease • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Oropharyngeal Cancer • Ovarian Cancer • Penile Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Vaginal Cancer • Vulvar Cancer • HLA-A • HLA-C • PRAME

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - Solid Tumor Program: Actively screening, enrolling, and dosing patients across the TCR-T therapy candidates; Update on solid tumor program expected by the end of 2024; Investigational new drug (IND) filing for TCR targeting MAGE-A4 on HLA-A*02:01 (TSC-202-A0201) planned by the end of the year; Response data for multiplex therapy anticipated in 2025."

IND • P1 data • Trial status • Oncology • Solid Tumor

First Patient Receives TCR-T Therapy in Multiplexed Study Screening Patients With Melanoma, Cervical Cancer and More (CGTLive) - "Screening is underway for participants with solid tumors to receive T-Plex, a multiplexed T-cell receptor-engineered T-cell (TCR-T) therapy, with 1 participant having received 1 Singleplex therapy so far in a phase 1 study (NCT05973487) with no acute toxicities....TSCAN-002 is a master protocol currently containing 6 TCR-Ts from a growing collection of TCR-Ts, called the ImmunoBank. Three TCR-Ts target MAGE-A1 across different HLA types, one targets MAGE-C2, one targets PRAME, and one targets HPV16."

Trial status • Cervical Cancer • Gynecologic Cancers • Head and Neck Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Non-Clinical Development of T-Plex Component TSC-201-B0702: A TCR-T Cell Therapy Directed to a Novel HLA-B*07:02 Restricted MAGE-C2 Epitope for the Treatment of Solid Tumors (ASGCT 2024) - "TSC-201-B0702 exhibits high specificity and potency against MAGE-C2-positive, HLA-B*07:02 tumor cells with no projected allo- or off-tumor reactivity. Based on these results, an IND for the clinical development of TSC-201-B0702 has been filed with the aim of incorporating TSC-201-B0702 in the ongoing T-Plex Phase 1 clinical trial master protocol. Plain Language Summary: T cells are designed to recognize cells that are infected with pathogens and eliminate them, but given the right tools, they can also recognize and eliminate rogue cells giving rise to cancer."

Clinical • Oncology • Solid Tumor • CD34 • CD8 • DHFR • HLA-B • IFNG • TGFB1

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire) - "TScan Therapeutics...announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually."

Preclinical • Solid Tumor

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) - "TScan Therapeutics, Inc...announced the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting....TScan’s Phase 1 solid tumor clinical trial is designed to assess customized, multiplexed TCR-T as a way to overcome tumor heterogeneity and HLA loss of heterozygosity. First generation TCR-T, targeting single antigens, has shown encouraging response rates (typically 30-50%), but has often shown short durations of response (3-4 months)....TScan is developing TSC-201-B0702, a TCR-T cell therapy that targets this epitope, with plans to file an IND by the end of the year. TCR-Ts targeting MAGE-C2 could potentially be used to treat up to 50% of melanoma patients, 25% of patients with head and neck cancers, and 50% of patients with NSCLC in the United States....'In addition to filing an IND for TSC-201-B0702, we also anticipate filing an IND for TSC-204-A0101 by the end of 2023'."

Clinical protocol • IND • Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities (GlobeNewswire) - "Initiate Phase 1 umbrella trial for TSC-100 following submission of clinical protocol to IRBs for the initial study sites, with plans to enroll patients in the first half of 2022...Progress IND-enabling studies for the TSC-200 series and submit two IND applications during the second half of 2022. These are expected to include TSC-200 for HPV and TSC-204 for MAGE-A1; In 2023, the Company plans to release initial clinical data for the TSC-200 series TCRs, as well as file further INDs for additional programs in this series."

Clinical data • IND • New P1 trial • Hematological Malignancies • Oncology • Solid Tumor

TScan Outlines 2022 Priorities as Programs Enter Clinic (GlobeNewswire) - "Following the IND submissions and pending acceptance by the FDA, the Company expects to initiate Phase 1 clinical trials for TSC-100 and TSC-101 in the first half of 2022, with preliminary data expected in the second half of 2022....TScan plans to present initial preclinical data on the TSC-2xx series at a medical meeting in the first half of 2022. TScan plans to progress IND-enabling studies for the TSC-2xx series and submit multiple IND applications during the second half of 2022."

IND • New P1 trial • P1 data • Preclinical • Hematological Malignancies • Oncology • Solid Tumor

TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies (GlobeNewswire) - "TScan Therapeutics...announced that it has completed the construction of a state-of-the-art GMP manufacturing facility to manufacture Phase I/II TCR-T therapies. This facility will support the manufacturing of TScan’s two lead liquid tumor candidates, TSC-100 and TSC-101, designed to eliminate residual leukemia and prevent relapse after hematopoietic cell transplantation for patients with hematological malignancies, as well as solid tumor candidates TSC-200, TSC-201, TSC-202 and TSC-203, designed to treat patients with solid tumors including head and neck, cervical, anal, melanoma and non-small cell lung cancers."

Commercial • Anal Carcinoma • Cervical Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor